A feasibility and safety study of bronchoscopic thermal vapor ablation: A novel emphysema therapy

Snell, Gregory I., Hopkins, Peter, Westall, Glen, Holsworth, Lynda, Carle, Anne and Williams, Trevor J. (2009) A feasibility and safety study of bronchoscopic thermal vapor ablation: A novel emphysema therapy. Annals of Thoracic Surgery, 88 6: 1993-1998. doi:10.1016/j.athoracsur.2009.06.038


Author Snell, Gregory I.
Hopkins, Peter
Westall, Glen
Holsworth, Lynda
Carle, Anne
Williams, Trevor J.
Title A feasibility and safety study of bronchoscopic thermal vapor ablation: A novel emphysema therapy
Journal name Annals of Thoracic Surgery   Check publisher's open access policy
ISSN 0003-4975
1552-6259
Publication date 2009-12
Sub-type Article (original research)
DOI 10.1016/j.athoracsur.2009.06.038
Volume 88
Issue 6
Start page 1993
End page 1998
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Language eng
Formatted abstract
Purpose:
This study reports the feasibility and safety of novel second-generation bronchoscopic lung volume reduction (LVR) technology, independent of collateral ventilation.

Description:
Eleven patients with severe heterogeneous emphysema underwent unilateral bronchoscopic application of vapor thermal energy (mean 4.9 cal/g alveolar tissue; range, 3 to 7.5) with bronchial thermal vapor ablation (BTVA) aiming to induce a controlled inflammatory airway and parenchymal response with resultant LVR.

Evaluation:

Nine women and 2 men, with a mean age of 61 years, forced expiratory volume in 1 second (FEV1) of 0.77 ± 0.17 L (32% predicted), residual volume (RV) of 4.1 ± 0.9 L (219% predicted), and gas transfer of 7.8 ± 2.2 (34% predicted), underwent unilateral upper lobe treatments. Serious adverse events in 5 included probable bacterial pneumonia and exacerbations of airways disease in 2. Although no important FEV1 or RV changes occurred during 6 months of follow-up, gas transfer improved, 16% to 9.0% ± 2.1% (38% predicted), the Medical Research Council Dyspnoea Score improved from 2.6 to 2.1, and the St. George Respiratory Questionnaire Total Score improved from 64.4 at baseline to 49.1.

Conclusions:
These preliminary data on unilateral BTVA therapy confirm feasibility, an acceptable safety profile, and the potential for efficacy.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 51 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 74 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 02 Nov 2011, 11:03:15 EST by System User on behalf of Medicine - Prince Charles Hospital